Date de publication
Géographie
Langue de la ressource
Texte disponible en version intégrale
Open Access / OK to Reproduce
Évalué par des pairs
L’objectif
In this study, we evaluate whether COVID-19 and subsequent opioid use disorder (OUD) treatment policies impacted receipt of therapy/counseling and medication for OUD (MOUD) for veterans.
Constatations/points à retenir
Veterans were less likely to receive therapy/counseling over time, especially post-pandemic onset, and despite substantial increases in teletherapy. The likelihood of receiving buprenorphine, methadone, and naltrexone was reduced post-pandemic onset. Percentage of days covered (PDC) on MOUD generally decreased over time, especially methadone PDC post-pandemic onset, whereas buprenorphine PDC was less impacted during COVID-19. The number of months prescribed methadone and buprenorphine represented relative improvements compared to prior years. We observed important disparities across Veteran demographics.
La conception ou méthodologie de recherche
Nationwide electronic health record data
